A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown ...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Yuexian Zhou, Huifang Zong, Lei Han, Yueqing Xie, Hua Jiang, John Gilly, Baohong Zhang, Huili Lu, Jie Chen, Rui Sun, Zhidi Pan and Jianwei Zhu Tags: Research Source Type: research